What's Happening?
Perfuze, a medical device company based in Galway, Ireland, has received FDA 510(k) clearance for its Millipede88 Aspiration Catheter. This device is the first super-bore aspiration catheter cleared for standalone direct aspiration, meaning it can be
used without a large-bore intermediary. The clearance follows the successful MARRS clinical study, which demonstrated high first-pass reperfusion rates and delivery success. The Millipede88's patented corrugated design simplifies navigation through complex neurovascular anatomy, maintaining maximum aspiration force. This innovation positions Perfuze as a leader in the super-bore aspiration segment, a rapidly growing area in the mechanical thrombectomy market.
Why It's Important?
The FDA clearance of the Millipede88 Aspiration Catheter is significant for the medical device industry and stroke treatment. It offers a new benchmark in aspiration technology, potentially reducing procedural complexity and costs while saving critical time during stroke interventions. The device's high first-pass reperfusion rates could improve clinical outcomes, making it a valuable tool for physicians. This development also strengthens Perfuze's position in the U.S. market, expanding its neurovascular portfolio and meeting the growing demand for advanced stroke treatment solutions.
What's Next?
Perfuze plans to initiate a Limited Market Release of the Millipede88 Aspiration Catheter in select U.S. Comprehensive Stroke Centers, with broader commercialization to follow. As the super-bore aspiration segment continues to grow, Perfuze is well-positioned to capture market share with its innovative technology. The company's focus on expanding its U.S. commercial footprint suggests further developments in its product offerings and potential collaborations with healthcare providers to enhance stroke treatment protocols.
